File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.ddmod.2012.02.003
- Scopus: eid_2-s2.0-84876690042
- Find via
Supplementary
-
Citations:
- Scopus: 0
- Appears in Collections:
Article: Human ESC/iPSC-based 'omics' and bioinformatics for translational research
| Title | Human ESC/iPSC-based 'omics' and bioinformatics for translational research |
|---|---|
| Authors | |
| Issue Date | 2012 |
| Citation | Drug Discovery Today: Disease Models, 2012, v. 9 n. 4, p. e161-e170 How to Cite? |
| Abstract | The establishment of human embryonic stem cell lines (hESCs) created the basis for new approaches in regenerative medicine and drug discovery. Despite the potential of hESCs for cell-based therapies, ethical controversies limit their use. These obstacles could be overcome by induced pluripotent stem cells (iPSCs) that are generated by reprogramming somatic cells. Before iPSCs can be used for clinical applications, however, they must be thoroughly analyzed for aberrations in the genome, epigenome, transcriptome and proteome. Here, we review how 'omics' technologies can be employed for a quantitative and definitive assessment of these cells. © 2012 Elsevier Ltd. All rights reserved. |
| Persistent Identifier | http://hdl.handle.net/10722/195143 |
| ISSN | 2020 SCImago Journal Rankings: 0.268 |
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Müller, GA | - |
| dc.contributor.author | Tarasov, KV | - |
| dc.contributor.author | Gundry, RL | - |
| dc.contributor.author | Boheler, KR | - |
| dc.date.accessioned | 2014-02-25T01:40:14Z | - |
| dc.date.available | 2014-02-25T01:40:14Z | - |
| dc.date.issued | 2012 | - |
| dc.identifier.citation | Drug Discovery Today: Disease Models, 2012, v. 9 n. 4, p. e161-e170 | - |
| dc.identifier.issn | 1740-6757 | - |
| dc.identifier.uri | http://hdl.handle.net/10722/195143 | - |
| dc.description.abstract | The establishment of human embryonic stem cell lines (hESCs) created the basis for new approaches in regenerative medicine and drug discovery. Despite the potential of hESCs for cell-based therapies, ethical controversies limit their use. These obstacles could be overcome by induced pluripotent stem cells (iPSCs) that are generated by reprogramming somatic cells. Before iPSCs can be used for clinical applications, however, they must be thoroughly analyzed for aberrations in the genome, epigenome, transcriptome and proteome. Here, we review how 'omics' technologies can be employed for a quantitative and definitive assessment of these cells. © 2012 Elsevier Ltd. All rights reserved. | - |
| dc.language | eng | - |
| dc.relation.ispartof | Drug Discovery Today: Disease Models | - |
| dc.title | Human ESC/iPSC-based 'omics' and bioinformatics for translational research | - |
| dc.type | Article | - |
| dc.description.nature | link_to_subscribed_fulltext | - |
| dc.identifier.doi | 10.1016/j.ddmod.2012.02.003 | - |
| dc.identifier.scopus | eid_2-s2.0-84876690042 | - |
| dc.identifier.volume | 9 | - |
| dc.identifier.issue | 4 | - |
| dc.identifier.spage | e161 | - |
| dc.identifier.epage | e170 | - |
| dc.identifier.issnl | 1740-6757 | - |